Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?

Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e006019. doi: 10.1161/CIRCOUTCOMES.119.006019. Epub 2020 Jan 10.
No abstract available

Keywords: PCSK9; approval rates; utilization.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / economics
  • Anticholesteremic Agents / therapeutic use*
  • Biomarkers / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / economics
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Cost-Benefit Analysis
  • Databases, Factual
  • Drug Approval* / economics
  • Drug Costs
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / economics
  • Dyslipidemias / epidemiology
  • Humans
  • Lipids / blood
  • PCSK9 Inhibitors*
  • Practice Patterns, Physicians' / economics
  • Practice Patterns, Physicians' / trends*
  • Proprotein Convertase 9
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Serine Proteinase Inhibitors / adverse effects
  • Serine Proteinase Inhibitors / economics
  • Serine Proteinase Inhibitors / therapeutic use*
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Lipids
  • PCSK9 Inhibitors
  • Serine Proteinase Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9